Boston Scientific shares fell following disclosures of a global cyberattack and a high-risk product recall.
The company identified a cyberattack on August 25 that triggered a global network outage. This disruption halted operational processes and blocked customer order shipments. Third-party experts are investigating the incident to determine the full impact and restoration timeline.
The FDA designated the recall of the ENROUTE Transcarotid Neuroprotection System as Class I, its most serious category. The agency warns that the device's arterial sheath tip may separate during use. This defect can cause severe complications, including stroke or the need for surgical retrieval. One serious injury is currently linked to the product defect.